21 February 2018
News and Views
Links and Services
The most recent issue of Alimentary Pharmacology & Therapeutics identifies predictors of response to infliximab in paediatric perianal Crohn's disease.
It is reported that 27–54% of paediatric patients with perianal Crohn's disease do not respond to
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors